David Meek­er starts the next chap­ter of his long biotech ca­reer as chair­man of the board

David Meek­er may be leav­ing Sanofi Gen­zyme af­ter a long run at the big Boston op­er­a­tion, but he’s stay­ing in biotech.

Meek­er re­cent­ly an­nounced …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.